GSKGLAXF 69 EV-to-EBIT is 11.52 as of Jul. 06, 2026, which is 24% below its 10-year median of 15.11. GuruFocus rates GLAXF with a GF Score™ of 69/100 and a GF Value™ of $21.82 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 689 Drug Manufacturers companies, GSK ranks better than 64.15% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, GSK's Enterprise Value is $126,007 Mil.
GSK's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $10,941 Mil. Therefore, GSK's EV-to-EBIT for today is 11.52.
The historical rank and industry rank for GSK's EV-to-EBIT or its related term are showing as below:
GLAXF'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8.77 Med: 15.11 Max: 60.35
Current: 11.8
During the past 13 years, the highest EV-to-EBIT of GSK was 60.35. The lowest was 8.77. And the median was 15.11.
GLAXF's EV-to-EBIT is ranked better than 64.15% of 689
companies
in the Drug Manufacturers industry
Industry Median: 16.01
vs GLAXF: 11.80
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
GSK's Enterprise Value for the quarter that ended in Mar. 2026 was $129,776 Mil.
GSK's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,941 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK EV-to-EBIT Related Terms
GSK EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for GSK's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, GSK's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where GSK's EV-to-EBIT falls into.
GSK's current Enterprise Value is $126,007 Mil.
GSK's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,941 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSK (GLAXF) has a EV-to-EBIT of 11.52 as of Jul. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GSK and its competitors. This is 24% below median its historical median of 15.11. Over the past decade, GSK's EV-to-EBIT has ranged from 8.77 to 60.35. According to the industry distribution chart, GSK ranks #247 out of 689 companies in the Drug Manufacturers industry, placing it in the top 35.8%.
Is GSK's EV-to-EBIT too high?
GSK's current EV-to-EBIT of 11.52 is 24% below median its 10-year median of 15.11. Over the past 10 years, this metric has ranged from a low of 8.77 to a high of 60.35. The Drug Manufacturers industry median EV-to-EBIT is 16.01. GSK's value of 11.52 is 28% below this industry median. Based on the distribution chart, GSK ranks #247 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GSK has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #247 out of 689 companies for EV-to-EBIT. This puts GSK in the upper half of its industry. The industry median EV-to-EBIT is 16.01. GSK's value of 11.52 is 28% below this benchmark. Historically, GSK's own EV-to-EBIT has ranged from 8.77 to 60.35 over the past decade. While the company's 10-year median is 15.11 vs. the industry median of 16.01, GSK has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.01, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current EV-to-EBIT of 11.52 is 28% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current EV-to-EBIT is 11.52, which is 24% below median its own 10-year median of 15.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.82, compared to a current price of $25.77 — trading 18.1% above its estimated fair value. The current EV-to-EBIT is 11.52, which is 24% below median its 10-year median of 15.11 and 28% below the Drug Manufacturers industry median of 16.01. GSK's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For GSK (GLAXF), the current EV-to-EBIT is 11.52 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.77 is trading 18.1% above its estimated GF Value™ of $21.82.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
EV-to-EBIT: 11.52 (24% below median its 10-year median of 15.11)
GF Value™: $21.82 vs. price of $25.77 (18.1% above fair value)
Industry Position: 28% below the Drug Manufacturers median (#247 of 689)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
69GF Score
Get the complete analysis for GLAXF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
